Flexion Therapeutics (NASDAQ:FLXN) was downgraded by equities research analysts at BidaskClub from a “hold” rating to a “sell” rating in a research note issued on Wednesday.

FLXN has been the subject of a number of other research reports. Zacks Investment Research lowered Flexion Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, August 13th. ValuEngine raised Flexion Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 2nd. Finally, Benchmark started coverage on Flexion Therapeutics in a report on Thursday, June 28th. They issued a “buy” rating and a $39.00 target price for the company. One analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $91.50.

FLXN stock opened at $22.09 on Wednesday. Flexion Therapeutics has a twelve month low of $19.06 and a twelve month high of $32.25. The company has a debt-to-equity ratio of 0.80, a current ratio of 12.90 and a quick ratio of 12.78. The company has a market cap of $828.16 million, a P/E ratio of -5.31 and a beta of 0.72.

Flexion Therapeutics (NASDAQ:FLXN) last posted its quarterly earnings data on Tuesday, August 7th. The specialty pharmaceutical company reported ($1.16) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($1.22) by $0.06. The company had revenue of $3.80 million for the quarter, compared to the consensus estimate of $3.96 million. equities research analysts forecast that Flexion Therapeutics will post -4.75 earnings per share for the current fiscal year.

In other Flexion Therapeutics news, CFO David Arkowitz bought 4,000 shares of Flexion Therapeutics stock in a transaction on Thursday, August 9th. The stock was acquired at an average price of $23.42 per share, with a total value of $93,680.00. Following the acquisition, the chief financial officer now owns 44,250 shares in the company, valued at $1,036,335. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Michael D. Clayman bought 10,000 shares of Flexion Therapeutics stock in a transaction on Thursday, August 9th. The stock was acquired at an average cost of $22.33 per share, with a total value of $223,300.00. Following the acquisition, the chief executive officer now owns 75,282 shares in the company, valued at approximately $1,681,047.06. The disclosure for this purchase can be found here. 14.59% of the stock is currently owned by company insiders.

Several institutional investors have recently bought and sold shares of the business. State Board of Administration of Florida Retirement System increased its holdings in shares of Flexion Therapeutics by 22.9% in the 2nd quarter. State Board of Administration of Florida Retirement System now owns 15,896 shares of the specialty pharmaceutical company’s stock worth $411,000 after purchasing an additional 2,960 shares in the last quarter. Redmile Group LLC grew its holdings in shares of Flexion Therapeutics by 33.5% in the second quarter. Redmile Group LLC now owns 13,260 shares of the specialty pharmaceutical company’s stock worth $343,000 after acquiring an additional 3,330 shares during the period. Swiss National Bank grew its holdings in shares of Flexion Therapeutics by 7.1% in the first quarter. Swiss National Bank now owns 51,311 shares of the specialty pharmaceutical company’s stock worth $1,150,000 after acquiring an additional 3,400 shares during the period. Alps Advisors Inc. grew its holdings in shares of Flexion Therapeutics by 8.5% in the second quarter. Alps Advisors Inc. now owns 54,622 shares of the specialty pharmaceutical company’s stock worth $1,412,000 after acquiring an additional 4,272 shares during the period. Finally, Schwab Charles Investment Management Inc. grew its holdings in shares of Flexion Therapeutics by 3.0% in the second quarter. Schwab Charles Investment Management Inc. now owns 179,658 shares of the specialty pharmaceutical company’s stock worth $4,645,000 after acquiring an additional 5,257 shares during the period. 99.10% of the stock is owned by institutional investors and hedge funds.

About Flexion Therapeutics

Flexion Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It lead product candidate includes Zilretta, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee.

Featured Article: What is a Leveraged Buyout (LBO)?

Analyst Recommendations for Flexion Therapeutics (NASDAQ:FLXN)

Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.